Vantage logo

Esker joins the Tyk2 race

The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.

Vantage logo

Point’s path leads to a Spac

The radiopharmaceutical researcher was negotiating a series B funding round when it got an offer from a Spac that it could not refuse.

Vantage logo

Onduo takes its time

The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.